Some long-term users run it year-round at maintenance doses
Disclosure of interest: Anastasios Mavridis: Nothing to Disclose, Adam Viktorisson: Nothing to Disclose, Bjrn Eliasson: Nothing to Disclose, Mia von Euler: Nothing to Disclose, Katharina S Sunnerhagen: Nothing to Disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS P999 - ESOC25-160 PREDICTORS OF 90-DAY OUTCOMES AND HEMORRHAGIC RISK AFTER ENDOVASCULAR THROMBECTOMY WITH STENT RELEASE IN PATIENTS WITH ACUTE CAROTID ARTERY ATHEROSCLEROTIC ISCHEMIC STROKE Gaia Mignani 1 , Marta Del Chicca 1 , Nicola Giannini 1 , Marco Baldini 1 , Roberto D'agliano 1 , Alessandro Grigolini 2 , Giacomo Petrucci 2 , Filippo Baldacci 1 , Mirco Cosottini 2 1 Neurological Clinic, University of Pisa, Pisa, Italy, 2 Neuroradiology Unit, University of Pisa, Pisa, Italy Background and Aims: To investigate clinical and procedural factors associated with the 90-day modified Rankin Scale (mRS) and symptomatic intracranial hemorrhage (sICH) at 6 and 12 hours after endovascular thrombectomy (EVT) with carotid stent release
Buy BPC-157 and TB-500 Peptide Blend From Limitless Biotech Limitless Biotech provides USA-manufactured BPC-157 and thymosin beta-4 for sale with verified molecular sequences and purity through comprehensive third-party testing
Perhaps most notably, the researchers observed no adverse effects even at high doses
